Avadel Pharmaceuticals   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Dublin Ireland (1990)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2020
NCT04451668
First Marketed Drug
2013
neostigmine (bloxiverz)
First NDA Approval
2013
neostigmine (bloxiverz)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Avadel | AVADEL CNS | AVADEL LEGACY | AVADEL SPECLT

Active Ingredients

Marketed Drugs (6)

Key: Avadel Pharmaceuticals (5) Acquired (1)

desmopressin (ddavp) (2017)

ephedrine (2016)

l-cysteine (cysteine hydrochloride) (2019)

neostigmine (bloxiverz) (2013 NDA)

phenylephrine (Prefrin) (2014)

sodium oxybate (xyrem) (2023)

Drugs in Phase 3 Trials (1)

Key: Avadel Pharmaceuticals (0) Acquired (1)

sodium oxybate (xyrem) (2 trials)

Drugs in Phase 2 Trials (5)

Key: Avadel Pharmaceuticals (0) Acquired (5)

fl-101 (3 trials)

fl-301 (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

nivolumab (opdivo) (1 trial)

ribavirin (virazole) (1 trial)

Indications

Approved Indications


 

Colonic Pseudo-Obstruction

Myasthenia Gravis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataplexy (Phase 3)

Disease (Phase 3)

Dyssomnias (Phase 3)

Narcolepsy (Phase 3)

Parasomnias (Phase 3)

Sleepiness (Phase 3)

Sleep Wake Disorders (Phase 3)

Overview

  • Highest Phase: None
  • # of Trials: 7
  • # of Trial APIs: 6